Norman John Carr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Norman John Carr has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
Leslie H. Sobin
Frederick National Laboratory for Cancer Research, National Cancer Institute, Rockville, MD
7 shared publicationsFaheez Mohamed
Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK
6 shared publications- Adrian Calvin Bateman
Department of Cellular Pathology University Hospital Southampton NHS Foundation Trust Southampton UK
4 shared publications Tom Cecil
Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK
4 shared publicationsAyaz Ahmed Memon
Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK
3 shared publicationsBrendan J. Moran
Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK
3 shared publications
Latest Publications
- 31 October 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 53 (1)
From consensus statements to clinical practice- PSOGI consensus recommendations clarifying optimal management of peritoneal malignancy
- 31 October 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 53 (1)
From consensus statements to clinical practice- PSOGI consensus recommendations clarifying optimal management of peritoneal malignancy
- 15 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (8) , 1481-1488
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
- 15 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (8) , 1481-1488
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
- Open Access
- 1 February 2022
- Published by Elsevier in Human Pathology
- Vol. 120, 77-87
Role of immunohistochemistry for interobserver agreement of Peritoneal Regression Grading Score in peritoneal metastasis
- 1 February 2022
- Published by Elsevier in Human Pathology
- Vol. 120, 77-87
Open AccessRole of immunohistochemistry for interobserver agreement of Peritoneal Regression Grading Score in peritoneal metastasis
- 5 November 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (4) , 2614-2615
ASO Author Reflections: Discordant Pathology in Pseudomyxoma Peritonei and Its Impact on Survival following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- 5 November 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (4) , 2614-2615
ASO Author Reflections: Discordant Pathology in Pseudomyxoma Peritonei and Its Impact on Survival following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- 3 November 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (4) , 2607-2613
Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology
The WHO classification of mucinous appendix neoplasms and pseudomyxoma peritonei (PMP) describes low- and high-grade histology and is of prognostic importa
- 3 November 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (4) , 2607-2613
Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology
The WHO classification of mucinous appendix neoplasms and pseudomyxoma peritonei (PMP) describes low- and high-grade histology and is of prognostic importa
- Open Access
- 1 April 2021
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 12 (S1) , S216-S229
New insights in the pathology of peritoneal surface malignancy
Pathology is central to the management of peritoneal surface malignancy. This article highlights some recent advances that have had an impact on patient management or could do so in the near future. Malignant peritoneal mesothelioma, particularly the epithelioid subtype, is amenable to radical therapy in selected cases, and factors such as ki67 proliferation index, expression of BAP1 and mutation in CDKN2A show promise as prognostic indicators. Our understanding of multicystic mesothelioma has improved in recent years; it is a true neoplasm for which surgery may be indicated. Serous carcinomas involving the peritoneum are now known to originate from tubal epithelium. They are of two distinct types, high grade and low grade, which are now recognized as different neoplasms with distinctive features, oncogenesis and behavior. Pseudomyxoma peritonei (PMP) is an unusual condition that usually arises from an appendiceal mucinous neoplasm. Recent consensus in the classification and nomenclature of these lesions is discussed, including the distinction between low grade and high grade appendiceal mucinous neoplasms (HAMN), and the diagnostic criteria for appendiceal adenocarcinoma. PMP is divided into four prognostic groups: acellular mucin, low grade mucinous carcinoma peritonei, high grade mucinous carcinoma peritonei, and high grade mucinous carcinoma peritonei with signet ring cells. The pseudomyxoma microbiome is a promising area for clinical intervention but has been the subject of little research activity. Goblet cell adenocarcinoma (previously known as ‘goblet cell carcinoid’) is a distinctive type of appendiceal adenocarcinoma. Its behavior correlates with histologic features, but no general consensus for classification has been reached.
- 1 April 2021
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 12 (S1) , S216-S229
Open AccessNew insights in the pathology of peritoneal surface malignancy
Pathology is central to the management of peritoneal surface malignancy. This article highlights some recent advances that have had an impact on patient management or could do so in the near future. Malignant peritoneal mesothelioma, particularly the epithelioid subtype, is amenable to radical therapy in selected cases, and factors such as ki67 proliferation index, expression of BAP1 and mutation in CDKN2A show promise as prognostic indicators. Our understanding of multicystic mesothelioma has improved in recent years; it is a true neoplasm for which surgery may be indicated. Serous carcinomas involving the peritoneum are now known to originate from tubal epithelium. They are of two distinct types, high grade and low grade, which are now recognized as different neoplasms with distinctive features, oncogenesis and behavior. Pseudomyxoma peritonei (PMP) is an unusual condition that usually arises from an appendiceal mucinous neoplasm. Recent consensus in the classification and nomenclature of these lesions is discussed, including the distinction between low grade and high grade appendiceal mucinous neoplasms (HAMN), and the diagnostic criteria for appendiceal adenocarcinoma. PMP is divided into four prognostic groups: acellular mucin, low grade mucinous carcinoma peritonei, high grade mucinous carcinoma peritonei, and high grade mucinous carcinoma peritonei with signet ring cells. The pseudomyxoma microbiome is a promising area for clinical intervention but has been the subject of little research activity. Goblet cell adenocarcinoma (previously known as ‘goblet cell carcinoid’) is a distinctive type of appendiceal adenocarcinoma. Its behavior correlates with histologic features, but no general consensus for classification has been reached.
- 1 September 2020
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 13 (3) , 469-484
Updates in Appendix Pathology
- 1 September 2020
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 13 (3) , 469-484
Updates in Appendix Pathology
- 17 December 2019
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 28 (4) , 367-370
Counting Intraepithelial Lymphocytes: A Comparison Between Routine Staining and CD3 Immunohistochemistry
Counting intraepithelial lymphocytes (IELs) is a key part of the assessment of duodenal biopsies. Immunohistochemistry (IHC) for CD3 can aid identification of lymphocytes in this context, but it is not evident that counts on hematoxylin and eosin (H&E) and CD3 are comparable. This study aimed to compare the IEL counts in duodenal biopsies using H&E stains and CD3 IHC, and to examine the interobserver variability. Thirty-five paired H&E and CD3 sections were reviewed by 6 pathologists who counted the number of IELs per 100 enterocytes. The counts were categorized into groups: normal (40 lymphocytes). CD3 IHC was associated with significantly higher IEL counts than H&E. Four cases with normal H&E counts had raised counts with CD3. There was moderate agreement between observers for both H&E and CD3. Lack of concordance between CD3 and H&E IEL counts suggests that counts derived from the 2 methods may not be comparable to each other and should not be considered equivalent. There was no significant improvement in interobserver variability with CD3 IHC.
- 17 December 2019
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 28 (4) , 367-370
Counting Intraepithelial Lymphocytes: A Comparison Between Routine Staining and CD3 Immunohistochemistry
Counting intraepithelial lymphocytes (IELs) is a key part of the assessment of duodenal biopsies. Immunohistochemistry (IHC) for CD3 can aid identification of lymphocytes in this context, but it is not evident that counts on hematoxylin and eosin (H&E) and CD3 are comparable. This study aimed to compare the IEL counts in duodenal biopsies using H&E stains and CD3 IHC, and to examine the interobserver variability. Thirty-five paired H&E and CD3 sections were reviewed by 6 pathologists who counted the number of IELs per 100 enterocytes. The counts were categorized into groups: normal (40 lymphocytes). CD3 IHC was associated with significantly higher IEL counts than H&E. Four cases with normal H&E counts had raised counts with CD3. There was moderate agreement between observers for both H&E and CD3. Lack of concordance between CD3 and H&E IEL counts suggests that counts derived from the 2 methods may not be comparable to each other and should not be considered equivalent. There was no significant improvement in interobserver variability with CD3 IHC.
- 19 June 2019
- Published by BMJ in Journal of Clinical Pathology
- Vol. 72 (9) , 639-641
Diagnostic concordance in cases of appendiceal mucinous neoplasia referred to a tertiary referral centre
Accurate diagnosis of appendiceal tumours and any associated peritoneal disease is clinically important but can be difficult. We retrieved the records of patients referred to the Peritoneal Malignancy Institute, Basingstoke, in the years 2016, 2017 and 2018 with a diagnosis of mucinous appendiceal neoplasia and identified 323 patients in which slides were reviewed as part of the referral pathway. Comparing the local report from the referring centre with the central review report, in 57 (18%) we identified a discrepancy. In 39 (12%) the discrepancy was in overall diagnosis, including 22 (7%) in which the local diagnosis was low-grade appendiceal mucinous neoplasm whereas the review diagnosis was reactive mucosal changes, usually due to ruptured diverticulum, with no evidence of neoplasia. Our findings support the practice of central review of histopathology slides by experienced pathologists at tertiary referral centres. They also suggest that improvements in diagnostic criteria are needed.
- 19 June 2019
- Published by BMJ in Journal of Clinical Pathology
- Vol. 72 (9) , 639-641
Diagnostic concordance in cases of appendiceal mucinous neoplasia referred to a tertiary referral centre
Accurate diagnosis of appendiceal tumours and any associated peritoneal disease is clinically important but can be difficult. We retrieved the records of patients referred to the Peritoneal Malignancy Institute, Basingstoke, in the years 2016, 2017 and 2018 with a diagnosis of mucinous appendiceal neoplasia and identified 323 patients in which slides were reviewed as part of the referral pathway. Comparing the local report from the referring centre with the central review report, in 57 (18%) we identified a discrepancy. In 39 (12%) the discrepancy was in overall diagnosis, including 22 (7%) in which the local diagnosis was low-grade appendiceal mucinous neoplasm whereas the review diagnosis was reactive mucosal changes, usually due to ruptured diverticulum, with no evidence of neoplasia. Our findings support the practice of central review of histopathology slides by experienced pathologists at tertiary referral centres. They also suggest that improvements in diagnostic criteria are needed.